From December 19 to 21, 2020, the 2020 (13th) China Pharmaceutical Strategy Conference, co-sponsored by the China Pharmaceutical Industry Information Center and the Central Youth Working Committee of the Peasants and Workers Party, was held in Shijiazhuang.
During the conference, the '2020 China Innovative Pharmaceutical Enterprises' list was released. After being awarded the China Innovative Pharmaceutical Enterprises in 2019, Haisco Pharmaceutical Group Co., Ltd. will once again be on the list of China's innovative pharmaceutical enterprises in 2020.
In recent years, domestic support policies in the field of innovative drugs have been frequently introduced, including drug review and approval reforms, pilot marketing authorization holder systems, and tax incentives. These policies have broken the policy barriers to new drug research and development and accelerated the progress of new drug research and development. Under the joint promotion of policies, capital, talents and other factors, pharmaceutical companies with outstanding R&D capabilities and strong new drug creation capabilities will stand out. The '2020 China Innovative Pharmaceutical Companies' list is selected to visually and vividly demonstrate the policy system of the innovative pharmaceutical industry and the spiritual outlook of innovative pharmaceutical companies under the development model, and to set a benchmark and contribute to the development of China's innovative pharmaceutical industry.
At the round table with the theme of 'How to Better Promote the Innovation and Transformation of the Pharmaceutical Industry', Ms. Fan Xiulian, founder of Haisco Pharmaceutical Group Co., Ltd., and Zhang Wei, Chairman of the Second Council of China Pharmaceutical Regulatory and Research Association, Lu Weigen, Vice President of the Industrial Research Institute, Tang Lida, Chief Scientist of Tianjin Pharmaceutical Research Institute, Cai Dongchen, Chairman of CSPC Holding Group Co., Ltd., Zhang Guimin, Chairman of Lunan Pharmaceutical Group Co., Ltd., Su Xuejun, Chairman of Shijiazhuang Siyao Group, and Yabao Pharmaceutical Ren Wuxian, Chairman of the Group Co., Ltd., had a wonderful discussion on topics such as 'China's pharmaceutical industry innovation and integration trends' and 'How Chinese companies are moving toward a world-class enterprise under the new situation'.
On December 14th, after the transformation and innovation of Haisco Pharmaceutical Group, the first independent original research and innovative drug of the first category of innovative drug cyclopofol injection (trade name: Sishuning) was launched. Cycloporol is a brand-new intravenous anesthetic drug with completely independent intellectual property rights developed by Haisco. The indication research carried out includes sedation in gastrointestinal endoscopy (approved for marketing) and general anesthesia induction (NDA application priority review ), sedation and/or anesthesia for bronchoscopy diagnosis and treatment (Phase III, completed), induction and maintenance of general anesthesia (Phase III), ICU sedation (Phase III), etc. Cycloprofen has a rich layout of indications. It is the drug with the most comprehensive indications among the intravenous anesthetics marketed in recent years. Its drug registration is classified as chemical drug category 1.
At present, Haisco has 9 innovative products in its pipeline, covering areas such as diabetes, analgesia, and tumors. Its strategy is to quickly follow the global frontier targets, develop Me-better drugs and strive for Best-In-Class. Haisco's R&D investment in innovative drugs has been maintained at a relatively high proportion. In 2020, R&D investment will almost be equal to profit, which is estimated to be around 600 million yuan.
From agency sales to establishing its own marketing team, from generic drugs to innovative drugs, Haisco continues to learn from leading companies and gradually enter a new stage of combining imitation and innovation. And now, the era of Haisco's innovative drugs has arrived.
Contact:
Tel: +86-0893-7834870
Email: haisco@haisco.com
Web: http://www.haisco.com
HAISCO PHARMACEUTICAL GROUP CO., LTD. 
